ClinicalTrials.gg
CompletedNCT04293679Updated Jun 9, 2022

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC

A Phase 1/2 interventional study of STP705 in Bowen's Disease and Cutaneous Squamous Cell Carcinoma in Situ, sponsored by Sirnaomics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-09.

Sponsored by Sirnaomics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2020, 6 years ago, and no results have been posted to the registry.
  • Registered 11 months after the study started (first participant enrolled Mar 2019, registered Feb 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open label, dose escalation study to evaluate the safety and efficacy of intralesional injection of STP705 in adult patients with Cutaneous Squamous Cell Carcinoma in situ (isSCC, Bowen's disease). The purpose of this trial is to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as Intralesional injection in subjects with isSCC.

Goals:

  • To determine the safe and effective recommended dose of STP705 for the treatment of isSCC.
  • Analysis of biomarkers common to isSCC formation pathway including TGF-β1 and COX-2.
Read the detailed description

This open label, dose escalation study is designed to evaluate the safety and efficacy of various doses of STP705 administered as an intralesional injection in subjects with cutaneous in situ squamous cell carcinoma (isSCC).

The primary objective of this study is to evaluate the safety, tolerability, and efficacy of various doses of STP705 administered as an Intralesional injection in subjects with cutaneous squamous cell carcinoma in situ skin cancer (isSCC). This study seeks to establish a safe and effective recommended dose of STP705 for the treatment of isSCC. Expression of biomarkers common to the isSCC formation pathway, including TGF-β1 and COX-2, will be evaluated.

The primary endpoint will be the proportion of participants with histological clearance of treated isSCC lesion at the End of Treatment (EOT). Histological clearance (HC) will be defined as the absence of detectable evidence of isSCC tumor cell nests as determined by central pathology review.

Secondary endpoints will include i) time to histological clearance of treated isSCC lesion over the 6 week treatment period, ii) proportion of participants with complete clinical clearance of treated isSCC lesion based on investigator assessment at the End of Treatment (EOT), iii) time to complete clinical clearance of treated isSCC lesion based on investigator assessment over the 6 week treatment period, and iv) the change in size of the treated isSCC lesion over the 6 week treatment period.

Safety and tolerability will be assessed by the number of incidence of adverse events (AEs) and serious adverse events (SAEs); the incidence of AEs and SAEs leading to discontinuation of trial medication; the incidence and severity of Local Skin Response (LSR); hypopigmentation and hyperpigmentation following treatment; and the tolerability of repeated Intralesional administration of STP705 as assessed by investigator-evaluation of injection site reactions for all patients and within each cohort.

In addition, safety measures will include clinically relevant changes or new abnormal findings in laboratory values, vital signs, electrocardiograms (ECGs), and physical examination variables.

25 adult patients are planned to be enrolled in the study. They will be divided equally among 5 cohorts (10, 20, 30, 60 and 120 μg dose levels) of 5 subjects each. Enrollment of the first two subjects in each dosing cohort will be staggered by at least 48 hours. Participants in the first cohort will attend the study center once weekly for an injection of STP705 into the isSCC lesion. The participants will receive injections of STP705 once a week for up to 6 weeks. The clinician will evaluate the tumor for clinical changes and reduction in size at each treatment visit for up to 6 weeks. If during the 6 weeks of treatment there is complete clinical clearance of the tumor, the treatments will end. At the End of Treatment visit, the residual tumor, or former tumor location will be excised for analysis. In the absence of dose limiting toxicities (DLT), the subsequent cohorts will receive increasing doses of STP705, following the same schedule of administration as the first cohort.

If any of the SAEs or dose limiting toxicities outlined above has occurred, the Data Safety Monitoring Board (DSMB) will conduct independent review of the data and will make a final decision for dose escalation to the next cohort.

02

Conditions studied

  • Bowen's Disease
  • Cutaneous Squamous Cell Carcinoma in Situ

Keywords

  • isSCC
  • Cutaneous Squamous Cell Carcinoma
  • STP705
  • Cutaneous Squamous Cell Carcinoma in situ
03

In context

Lead sponsor

Sirnaomics is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Male or female adult ≥ 18 years of age.
    1. Primary, confirmed trunk or extremity (non-peri-orbital/-anogenital/-facial/-scalp) isSCC lesion suitable for excision with a minimum diameter of 0.5cm and with a maximum diameter of 2.0cm.
    1. Histological diagnosis made no more than 6 months prior to the screening visit.
    1. Histological removed ≤25% of the original area of the target lesion.
    1. No other dermatological disease in the isSCC target site or surrounding area, which in the opinion of the investigator, could interfere with the study.
    1. Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period.
    1. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.
    1. Laboratory values for the tests (listed in the Study Schedule) within the reference ranges as defined by the central laboratory, or "out of range" test results that is clinically acceptable to the investigator. Acceptable "out of range" values are generally those within 2 standard deviations of the mean or explainable due to concurrent medications or disease processes.
    1. Ability to follow study instructions and likely to complete all study requirements.
    1. Written obtained, including consent for tissue to be examined and stored by the Central Histology Lab.
    1. Written consent to allow photographs of the target isSCC lesion to be used as part of the study data and documentation.
    1. For females of , a negative pregnancy test at screening and using an acceptable form of (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy).

Exclusion criteria

Exclusion Criteria:

    1. Pregnant or lactating.
    1. Presence of known or suspected systemic cancer.
    1. Histological evidence of nBCC, sBCC, invasive SCC, or any other non-isSCC tumor in the specimen.
    1. Histological evidence of severe squamous metaplasia, infiltrative, desomoplastic or micronodular growth patterns in the biopsy specimen.
    1. History of recurrence of the target isSCC lesion.
    1. Prior exposure to STP705.
    1. Evidence of dermatological disease or confounding skin condition in the treatment area, e.g., BCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa.
    1. Concurrent disease or treatment that suppresses the immune system;
    1. Patients with baseline QTC > 480 msec using Frederica's formula
    1. Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk.
    1. Known sensitivity to any of the ingredients in the study medication.
    1. Use of a tanning beds or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the study.
    1. Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit.
    1. Use of systemic retinoids within the 6 months prior to the screening period.
    1. Treatment with systemic immunomodulators or within the 6 months prior to the screening period.
    1. Use of topical immunomodulators within 2cm of the target isSCC lesion within the 4 weeks prior to the screening period.
    1. Treatment with the following topical agents within 2cm of the target isSCC lesion within the 4 weeks prior to the screening visit: amino-levulanic acid, 5-fluorouracil, , retinoids, diclofenac, ingenol mebutate, or imiquimod.
    1. Treatment with liquid nitrogen, surgical excision (excluding diagnostic incisional biopsy) or curettage within 2cm of the target isSCC lesion during the 4 weeks prior to the screening visit.
    1. Elective surgery within 4 weeks prior to the screening visit, during the study, or 4 weeks after the study period.
    1. Evidence of current chronic alcohol or drug abuse.
    1. Current enrollment in an drug or device study or participation in such a study within 4 weeks of the screening visit.
    1. In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.
    1. Taking any investigational product within 1 month of first dose of STP705.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Cohort A: STP705 10 μg dose

    Cohort A: STP705 10 μg dose, intradermal injection, given once a week for up to 6 weeks

    Drug: STP705

  • Experimental
    Cohort B: STP705 20 μg dose

    Cohort B: STP705 20 μg dose, intradermal injection, given once a week for up to 6 weeks

    Drug: STP705

  • Experimental
    Cohort C: STP705 30 μg dose

    Cohort C: STP705 30 μg dose, intradermal injection, given once a week for up to 6 weeks

    Drug: STP705

  • Experimental
    Cohort D: STP705 60 μg dose

    Cohort D: STP705 60 μg dose, intradermal injection, given once a week for up to 6 weeks

    Drug: STP705

  • Experimental
    Cohort E: STP705 120 μg dose

    Cohort E: STP705 120 μg dose, intradermal injection, given once a week for up to 6 weeks

    Drug: STP705

Interventions

  • DrugSTP705

    Investigational Product

06

What researchers measure

Primary outcomes

  1. Proportion of participants with histological clearance of treated isSCC lesion at the End of Treatment (EOT).

    Proportion of participants with histological clearance of treated isSCC lesion at the End of Treatment (EOT). Histological clearance (HC) will be defined as the absence of detectable evidence of isSCC tumor cell nests as determined by central pathology review.

    Time frame: 6 weeks

Secondary outcomes

  1. Time to histological clearance of treated isSCC lesion over the 6 week treatment period.

    Time frame: over the 6 week treatment period

  2. Proportion of participants with complete clinical clearance of treated isSCC lesion based on investigator assessment at the End of Treatment (EOT).

    Time frame: 6 weeks

  3. Time to complete clinical clearance of treated isSCC lesion based on investigator assessment over the 6 week treatment period.

    Time frame: over the 6 week treatment period

  4. Change in size of the treated isSCC lesion over the 6 week treatment period.

    Change in size of the treated isSCC lesion over the 6 week treatment period. A base line assessment of lesion size will be made by investigator at T1 (first visit, Day 0). The change in size will be assessed every week until the surgical excision of isSCC at the End of Treatment visit (EOT, Day 42) .

    Time frame: over the 6 week treatment period

07

Study locations

1 site
  • Center for Clinical and Cosmetic Research
    Aventura, Florida 33180, United States
08

References and documents

Publications

  • Kuzbicki L, Brozyna AA. Expression of Cyclooxygenase-2 in Human Epithelial Skin Lesions: A Systematic Review of Immunohistochemical Studies. Appl Immunohistochem Mol Morphol. 2021 Mar 1;29(3):163-174. doi: 10.1097/PAI.0000000000000871. PubMed 32889812 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Oct 2020, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2020
First posted
Mar 3, 2020
StartActual
Mar 21, 2019
Primary completionActual
Oct 21, 2020
CompletionActual
Oct 21, 2020
Last update
Jun 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04293679
Lead sponsor
Sirnaomics
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Mar 3, 2020
Start date
Mar 21, 2019
Primary completion
Oct 21, 2020
Completion
Oct 21, 2020
Last update
Jun 9, 2022

Study contacts

Kush Dhody, MBBS, MS, CCRA
study director · Amarex Clinical Research, LLC (Amarex)
Brian Berman, MD, PhD
principal investigator · Center for Clinical and Cosmetic Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cotsiranib

Start the discussion